|
Circulating anticoagulants are usually autoantibodies that neutralize specific clotting factors in vivo (eg, an autoantibody against factor VIII or factor V) or inhibit protein-bound phospholipid in vitro. Occasionally, the latter type of autoantibody causes bleeding in vivo by binding prothrombin.
Circulating anticoagulants should be suspected in patients with excessive bleeding combined with either a prolonged PTT or PT that does not correct when the test is repeated with a 1:1 mixture of normal plasma and the patient's plasma.
Antiphospholipid antibodies (see Thrombotic Disorders: Antiphospholipid Antibody Syndrome) typically cause thrombosis. However, in a subset of patients, the antibodies bind to prothrombin-phospholipid complexes, inducing hypoprothrombinemia; these patients may bleed excessively.
Factor
VIII Anticoagulants
Isoantibodies to factor VIII develop in about 15 to 35% of patients with severe hemophilia A as a complication of repeated exposure to normal factor VIII molecules during replacement therapy (see Coagulation Disorders: Hemophilia). Factor VIII autoantibodies also arise occasionally in nonhemophilic patients, eg, in a postpartum woman as a manifestation of underlying systemic autoimmune disease or of transiently disordered immune regulation, or in elderly patients without overt evidence of other underlying disease. Patients with a factor VIII anticoagulant can develop life-threatening hemorrhage.
Plasma containing a factor VIII antibody has a prolonged PTT that does not correct when normal plasma or another source of factor VIII is added in a 1:1 mixture to the patient's plasma. Testing is performed immediately after mixture and again after incubation.
Therapy with cyclophosphamide and corticosteroids may suppress autoantibody production in patients without hemophilia. In postpartum women, the autoantibodies may disappear spontaneously. Management of acute hemorrhage in hemophilic patients who have factor VIII isoantibodies is discussed in Coagulation Disorders: Prevention and Treatment.
Last full review/revision November 2005
Content last modified November 2005
| 
